Suppr超能文献

流式细胞术交叉配型检测的实验室间变异性评估:能力验证调查的经验教训

Assessment of Inter-Laboratory Variability for Flow Cytometric Crossmatch Testing: Lessons Learned from Proficiency Surveys.

作者信息

Philogene Mary Carmelle, Timofeeva Olga A, Gimferrer Idoia, Hod-Dvorai Reut

机构信息

Histocompatibility and Immunogenetics Laboratory, Virginia Commonwealth University, Richmond, VA, United States.

UCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, United States.

出版信息

Hum Immunol. 2025 Jan;86(1):111176. doi: 10.1016/j.humimm.2024.111176. Epub 2024 Dec 2.

Abstract

Detection of antibody directed against human leukocyte antigens (HLA) using a combination of flow cytometric crossmatch (FCXM) and antibody tests, is an important responsibility of Histocompatibility laboratories. Proficiency testing surveys utilize the results of these assays to assess concordance across multiple laboratories. In this study, we reviewed the ASHI Proficiency Testing (PT) antibody and crossmatching (AC) survey results obtained over a 6-year period, to evaluate the degree and nature of inter-laboratory FCXM and antibody assay variability. National and international laboratories representing 22 countries produced >10,000 T cell and >10,000 B cell FCXM results. Based on the 80% consensus threshold established for FCXM surveys, 92.5% T cell FCXM and 91.7% B cell FCXM results reached positive or negative consensus and were respectively consistent with the presence or absence of donor specific HLA antibodies (DSA) that reached a 90% consensus. The 7.5% of T cell and 8.3% of B cell FCXM results that did not reach consensus were associated with a combination of consensus and non-consensus DSA. This analysis shows that despite differences in testing protocols and algorithms, there is good consensus for the FCXM assay among laboratories. The data show correlation between FCXM and bead-based assays and support the use of both for reliable information when assessing immunological risk.

摘要

采用流式细胞仪交叉配型(FCXM)和抗体检测相结合的方法检测抗人类白细胞抗原(HLA)抗体,是组织相容性实验室的一项重要职责。能力验证调查利用这些检测结果来评估多个实验室之间的一致性。在本研究中,我们回顾了6年期间获得的美国组织相容性与免疫遗传学学会(ASHI)能力验证(PT)抗体和交叉配型(AC)调查结果,以评估实验室间FCXM和抗体检测变异性的程度和性质。代表22个国家的国内和国际实验室产生了超过10,000个T细胞和超过10,000个B细胞的FCXM结果。基于为FCXM调查设定的80%一致性阈值,92.5%的T细胞FCXM结果和91.7%的B细胞FCXM结果达成了阳性或阴性共识,分别与达到90%共识的供体特异性HLA抗体(DSA)的存在或不存在一致。未达成共识的7.5%的T细胞和8.3%的B细胞FCXM结果与达成共识和未达成共识的DSA组合相关。该分析表明,尽管检测方案和算法存在差异,但各实验室之间对FCXM检测仍有良好的共识。数据显示FCXM与基于微珠的检测之间存在相关性,并支持在评估免疫风险时同时使用两者以获取可靠信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验